GKOS GLAUKOS Corp

  1. Stocks
  2. Healthcare
  3. NYSE: GKOS

Price (delayed)

$119.82

Market cap

$6.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.88

Enterprise value

$6.37B

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, ...

Highlights
The company's gross profit rose by 14% YoY and by 4% QoQ
The revenue has grown by 13% YoY and by 3.7% from the previous quarter
The quick ratio has contracted by 23% YoY and by 2.4% from the previous quarter
GLAUKOS's equity has decreased by 11% YoY and by 2.4% QoQ
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.glaukos.com
Peers: IART SRDX AVGR ICUI

Key stats

What are the main financial stats of GKOS
Market
Shares outstanding
50.37M
Market cap
$6.04B
Enterprise value
$6.37B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.15
Price to sales (P/S)
18.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.51
Earnings
Revenue
$326.43M
EBIT
-$126.29M
EBITDA
-$87.67M
Free cash flow
-$75.17M
Per share
EPS
-$2.88
Free cash flow per share
-$1.52
Book value per share
$9.11
Revenue per share
$6.58
TBVPS
$11.8
Balance sheet
Total assets
$933.34M
Total liabilities
$482.61M
Debt
$383.52M
Equity
$450.73M
Working capital
$316.37M
Liquidity
Debt to equity
0.85
Current ratio
5.38
Quick ratio
4.5
Net debt/EBITDA
-3.82
Margins
EBITDA margin
-26.9%
Gross margin
76.2%
Net margin
-43.2%
Operating margin
-41.3%
Efficiency
Return on assets
-14.9%
Return on equity
-30%
Return on invested capital
-15.5%
Return on capital employed
-14.7%
Return on sales
-38.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GKOS stock price

How has the GLAUKOS stock price performed over time
Intraday
1.84%
1 week
-0.75%
1 month
2.71%
1 year
57.74%
YTD
50.74%
QTD
1.24%

Financial performance

How have GLAUKOS's revenue and profit performed over time
Revenue
$326.43M
Gross profit
$248.67M
Operating income
-$134.77M
Net income
-$140.87M
Gross margin
76.2%
Net margin
-43.2%
The company's gross profit rose by 14% YoY and by 4% QoQ
The revenue has grown by 13% YoY and by 3.7% from the previous quarter
The net margin has increased by 10% YoY
GKOS's operating income is down by 8% YoY and by 4.7% QoQ

Growth

What is GLAUKOS's growth rate over time

Valuation

What is GLAUKOS stock price valuation
P/E
N/A
P/B
13.15
P/S
18.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.51
GLAUKOS's EPS has decreased by 3.6% from the previous quarter
The price to book (P/B) is 135% more than the 5-year quarterly average of 5.5 and 54% more than the last 4 quarters average of 8.4
GLAUKOS's equity has decreased by 11% YoY and by 2.4% QoQ
The P/S is 75% higher than the 5-year quarterly average of 10.2 and 42% higher than the last 4 quarters average of 12.6
The revenue has grown by 13% YoY and by 3.7% from the previous quarter

Efficiency

How efficient is GLAUKOS business performance
The ROE has contracted by 16% YoY and by 8% from the previous quarter
GLAUKOS's ROS has increased by 10% YoY
The return on assets has declined by 7% year-on-year and by 6% since the previous quarter
The ROIC is down by 4.7% since the previous quarter and by 4% year-on-year

Dividends

What is GKOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GKOS.

Financial health

How did GLAUKOS financials performed over time
The total assets is 93% greater than the total liabilities
The quick ratio has contracted by 23% YoY and by 2.4% from the previous quarter
GKOS's current ratio is down by 19% year-on-year
The debt is 15% lower than the equity
The debt to equity has grown by 13% YoY and by 2.4% from the previous quarter
GLAUKOS's equity has decreased by 11% YoY and by 2.4% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.